Fylnetra (pegfilgrastim) NDC 70121-1627 · J-Code J2506

NDC codes

FDA NDC Directory

Product NDC (as listed)70121-1627Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70121-1627Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70121-1627-1	70121162701	1 SYRINGE in 1 CARTON (70121-1627-1) / .6 mL in 1 SYRINGEMarketed from May 31, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fylnetra
Generic name (nonproprietary): pegfilgrastim
Active ingredients: Pegfilgrastim — 6 mg/.6mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Amneal Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761084
Marketing start: May 31, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Granulocyte Colony-Stimulating Factor (Chemical structure)Increased Myeloid Cell Production (Physiologic effect)
Identifiers: Product ID 70121-1627_8cb6cfed-487e-4351-8f48-0be3cc5c2d6dSPL ID 8cb6cfed-487e-4351-8f48-0be3cc5c2d6dSPL set ID eeadd641-573d-47fe-897a-61006e5f9e03RxCUI 2602781, 2602787UNII 3A58010674UPC 0370121162711, 0470121162718
Pharmacologic class: Leukocyte Growth Factor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J2506 — Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Billing unit: 0.5 mg. Units on the claim = dose given ÷ 0.5 mg.

Pegfilgrastim biosimilars have their own HCPCS codes.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470121162701 followed by a unit qualifier and the quantity

Package 70121-1627-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 25, 2025.

Indications (excerpt from the label)

FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2) Limitations of Use FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy FYLNETRA is indicated to decrease the inciden…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)